Literature DB >> 34040082

Analysis of the intracellular traffic of IgG in the context of Down syndrome (trisomy 21).

R B Cejas1, M Tamaño-Blanco1, J G Blanco2.   

Abstract

Persons with Down syndrome (DS, trisomy 21) have widespread cellular protein trafficking defects. There is a paucity of data describing the intracellular transport of IgG in the context of endosomal-lysosomal alterations linked to trisomy 21. In this study, we analyzed the intracellular traffic of IgG mediated by the human neonatal Fc receptor (FcRn) in fibroblast cell lines with trisomy 21. Intracellular IgG trafficking studies in live cells showed that fibroblasts with trisomy 21 exhibit higher proportion of IgG in lysosomes (~ 10% increase), decreased IgG content in intracellular vesicles (~ 9% decrease), and a trend towards decreased IgG recycling (~ 55% decrease) in comparison to diploid cells. Amyloid-beta precursor protein (APP) overexpression in diploid fibroblasts replicated the increase in IgG sorting to the degradative pathway observed in cells with trisomy 21. The impact of APP on the expression of FCGRT (alpha chain component of FcRn) was investigated by APP knock down and overexpression of the APP protein. APP knock down increased the expression of FCGRT mRNA by ~ 60% in both diploid and trisomic cells. Overexpression of APP in diploid fibroblasts and HepG2 cells resulted in a decrease in FCGRT and FcRn expression. Our results indicate that the intracellular traffic of IgG is altered in cells with trisomy 21. This study lays the foundation for future investigations into the role of FcRn in the context of DS.

Entities:  

Year:  2021        PMID: 34040082     DOI: 10.1038/s41598-021-90469-z

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  58 in total

1.  Defective B-cell memory in patients with Down syndrome.

Authors:  Ruud H J Verstegen; Gertjan J Driessen; Sophinus J W Bartol; Carel J M van Noesel; Louis Boon; Mirjam van der Burg; Jacques J M van Dongen; Esther de Vries; Menno C van Zelm
Journal:  J Allergy Clin Immunol       Date:  2014-08-23       Impact factor: 10.793

2.  Palivizumab use in infants with Down syndrome-report from the German Synagis™ Registry 2009-2016.

Authors:  Arne Simon; Susanne Gehrmann; Gudrun Wagenpfeil; Stefan Wagenpfeil
Journal:  Eur J Pediatr       Date:  2018-04-12       Impact factor: 3.183

Review 3.  Down syndrome: issues to consider in a national registry, research database and biobank.

Authors:  Linda L McCabe; Edward R B McCabe
Journal:  Mol Genet Metab       Date:  2011-03-26       Impact factor: 4.797

4.  Humoral immunodeficiencies in Down syndrome: serum IgG subclass and antibody response to hepatitis B vaccine.

Authors:  M A Avanzini; V Monafo; M De Amici; R Maccario; G R Burgio; A Plebani; A G Ugazio; L A Hanson
Journal:  Am J Med Genet Suppl       Date:  1990

5.  Down Syndrome and the Risk of Severe RSV Infection: A Meta-analysis.

Authors:  Andrea A Beckhaus; Jose A Castro-Rodriguez
Journal:  Pediatrics       Date:  2018-08-09       Impact factor: 7.124

Review 6.  Pharmacotherapeutic Considerations for Individuals with Down Syndrome.

Authors:  Erik Hefti; Javier G Blanco
Journal:  Pharmacotherapy       Date:  2017-01-13       Impact factor: 4.705

7.  Antibody response to pneumococcal capsular polysaccharide vaccine in Down syndrome patients.

Authors:  B T Costa-Carvalho; R M A Martinez; A T N Dias; C A Kubo; P Barros-Nunes; L Leiva; D Solé; M M S Carneiro-Sampaio; C K Naspitz; R U Sorensen
Journal:  Braz J Med Biol Res       Date:  2006-12       Impact factor: 2.590

8.  Associated congenital anomalies among cases with Down syndrome.

Authors:  Claude Stoll; Beatrice Dott; Yves Alembik; Marie-Paule Roth
Journal:  Eur J Med Genet       Date:  2015-11-11       Impact factor: 2.708

9.  Estimation of the number of people with Down syndrome in the United States.

Authors:  Gert de Graaf; Frank Buckley; Brian G Skotko
Journal:  Genet Med       Date:  2016-09-08       Impact factor: 8.822

10.  Ethnicity, sex, and the incidence of congenital heart defects: a report from the National Down Syndrome Project.

Authors:  Sallie B Freeman; Lora H Bean; Emily G Allen; Stuart W Tinker; Adam E Locke; Charlotte Druschel; Charlotte A Hobbs; Paul A Romitti; Marjorie H Royle; Claudine P Torfs; Kenneth J Dooley; Stephanie L Sherman
Journal:  Genet Med       Date:  2008-03       Impact factor: 8.822

View more
  2 in total

1.  Down Syndrome Fetal Fibroblasts Display Alterations of Endosomal Trafficking Possibly due to SYNJ1 Overexpression.

Authors:  Laura De Rosa; Dominga Fasano; Lucrezia Zerillo; Valeria Valente; Antonella Izzo; Nunzia Mollo; Giuseppina Amodio; Elena Polishchuk; Roman Polishchuk; Mariarosa Anna Beatrice Melone; Chiara Criscuolo; Anna Conti; Lucio Nitsch; Paolo Remondelli; Giovanna Maria Pierantoni; Simona Paladino
Journal:  Front Genet       Date:  2022-05-13       Impact factor: 4.772

2.  Drug-Targeted Genomes: Mutability of Ion Channels and GPCRs.

Authors:  Regan Raines; Ian McKnight; Hunter White; Kaitlyn Legg; Chan Lee; Wei Li; Peter H U Lee; Joon W Shim
Journal:  Biomedicines       Date:  2022-03-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.